CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 30, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II clinical data on its next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), at the ESMO Congress 2025, taking place October 17-21, 2025, in Berlin, Germany.

MSS mCRC remains a therapeutic challenge with limited response to immune checkpoint inhibitors. Preclinical evidence supports the synergistic antitumor activity of CTLA-4 blockade combined with PD-(L)1 inhibition in mouse models. In this multicenter, open-label, Phase II study (NCT05167071), heavily pretreated non-liver metastatic MSS mCRC patients were enrolled. Preliminary efficacy and safety data will be presented in a poster session during the ESMO Congress 2025.

Details of the poster presentation are as follows:

Title: Efficacy and Safety of HBM4003, an anti-CTLA-4 Antibody, Combined with Tislelizumab in MSS Metastatic Colorectal Cancer: A Multicenter, Phase II Study

Presentation Number: 807P

Speaker: Frank Zheng

All accepted abstracts will be published online on the ESMO website.

About Porustobart (HBM4003)

Porustobart (HBM4003) is a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice^® platform. It is also the first fully human heavy-chain-only antibody which entered clinical development globally. Compared with conventional CTLA-4 antibodies, porustobart has unique, favorable properties, including significant Treg cell depletion and optimized pharmacokinetics for improved safety. Additionally, by enhancing antibody-dependent cellular cytotoxicity (ADCC), porustobart increases the potential to selectively deplete intratumoral Treg cells, helping to overcome the efficacy and toxicity bottleneck of current CTLA-4 therapies. Harbour BioMed has implemented a global development plan for multiple types of solid tumors with an adaptive treatment design for porustobart. Positive efficacy and safety data have been observed in the monotherapy trials targeting advanced solid tumors, as well as in combination trials with PD-1 inhibitors for melanoma, CRC, NEN and HCC.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice^®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICA^TM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice^®, HBICE^®, and HBICA^TM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

As H2G innovates in novel hydrogen production technologies, the biochar byproducts of its process will be refined and commercialised under the agreement.

SINGAPORE, July 30, 2025 /PRNewswire/ — H2G Green Limited (SGX:5AI) (“H2G” or the “Company“, together with its subsidiaries, collectively the “Group“), a leader in sustainable energy solutions, and its subsidiary Green Energy Investment Holding Private Limited (“GEIH“) today announced a licence agreement with Singapore’s Agency for Science, Technology and Research (“A*STAR“).

GEIH is an innovator in sustainable hydrogen with proprietary technologies that repurposes and transforms waste biomass into green hydrogen, as well as biochar and other high-value, sustainable materials. GEIH will commercialise a proprietary treatment process by A*STAR Institute of Materials Research and Engineering (A*STAR IMRE) to purify biochar, a by-product, into high-value hard carbon material for market use. Hard carbon materials are primarily used as anodes for batteries such as sodium-ion and lithium-ion batteries, due to their unique properties. They are also found in applications for water and air purifications as well as conductive additive in paints and coatings.

Following execution of the licence agreement, GEIH and A*STAR will begin the next phase of scaling up to accelerate the commercialisation pathway of the biochar purification process, focusing on producing hard carbon as anodes for use in sodium-ion batteries.

Mr. Sydney Kwan, CEO of GEIH, remarked: “We are deeply grateful to A*STAR for their ongoing collaboration and support. Our joint efforts are transforming the nation into a hub for sustainable technologies and green energy.”

An earlier exploratory phase found that the hard carbon GEIH produces tends to be superior to existing commercial materials due to a high graphite content, which makes the material favourable for anodes in sodium-ion batteries. These have possible applications for grid-scale energy storage, electric vehicles, and consumer electronics. The abundance of sodium makes sodium-ion batteries a more sustainable alternative to lithium-ion batteries.

GEIH’s technologies make it especially suited to this endeavour. The Company’s proprietary high-temperature thermochemical process turns any type of biomass without silica into hydrogen, biochar, bio-oil (for sustainable aviation fuel), and wood vinegar. The entire process incorporates circularity of materials as a guiding principle, and production of biochar results from incorporating carbon sequestration. The output materials power sectors as diverse as data centres, wafer fabrication, construction, agriculture, food manufacturing, laundry services, and central kitchens.

Mr. Pek Hak Bin, CEO of H2G, added: “Hydrogen is the energy of the future and a core part of Singapore’s low-carbon energy strategy. H2G is expanding possibilities for Singapore and beyond by pioneering a novel hydrogen production process that is cost-effective, less carbon intensive than electrolysis, and repurposes waste into sustainable materials. These power sustainable industries, as our hard carbon anode materials for sodium-ion batteries will empower a broader range of industries to reduce their environmental impact. In this way, H2G creates win-win-win sustainability solutions to multiple problems across industries.”

About H2G Green Limited

H2G focuses on delivering sustainable energy solutions through its two subsidiaries: GasHubUnited Utility Private Limited (“GasHub“) for LNG and GEIH for hydrogen, biochar, and other high-value, sustainable materials. In Singapore, the Company is working towards solving the energy trilemma — advancing cost competitiveness of sustainable energies, expanding energy security, and transitioning to net zero. Beyond Singapore, the Company is powering Southeast Asia’s transition towards cleaner, sustainable energy solutions. H2G stands out for deep engineering, energy, and sustainability expertise and an unwavering commitment to safety.

For more information about H2G and GEIH, please visit: https://h2g.green.

Media & Investor Contacts:

Tel: (+65) 6741 3939
Email: h2g@h2g.green

• Approval Underscores Technological Excellence and Commercial Viability amid Challenging Market Conditions
• Positioned to Become the First AI Optimization Company on KOSDAQ, Accelerating Global Expansion Efforts

SEOUL, South Korea, July 30, 2025 /PRNewswire/ — Nota AI, a leading provider of AI model optimization technology, today announced that it has received preliminary approval for a KOSDAQ listing, granted by the Korea Exchange. The company secured the approval just two months after filing, following its “A•A” rating in Korea’s official technology evaluation process last December. Nota AI aims to complete its IPO in the second half of 2025, with Mirae Asset Securities serving as the lead underwriter.

This swift approval is particularly noteworthy given the heightened regulatory scrutiny and sharp decline in IPO approvals during the first half of 2025. Nota AI’s success highlights its ability to meet increasingly stringent standards for both technological innovation and commercial viability. A key factor in the approval was the company’s proven track record of overseas customer wins and consistent revenue growth.

At the core of Nota AI’s value proposition is its proprietary platform, NetsPresso®—an end-to-end solution for developing and deploying lightweight, efficient AI models. The company has already commercialized this technology through collaborations with global semiconductor leaders, including NVIDIA, Samsung Electronics, Arm, Qualcomm, Sony, and Renesas.

Building on this foundation, Nota AI has expanded into key verticals—such as industrial safety, surveillance, and intelligent transportation systems (ITS)—through strategic contracts and successful commercial deployments. Among the solutions supporting these initiatives is the Nota Vision Agent (NVA), an advanced video monitoring system powered by the company’s proprietary Vision Language Model (VLM).

Notably, in April 2025, Nota AI signed a supply agreement with Dubai’s Roads and Transport Authority (RTA), becoming the first Korean company to deliver a generative AI solution to a government agency in the Middle East.

“This fast-track approval, amid today’s rigorous IPO environment, demonstrates that Nota AI is more than just a promising startup—we’re a globally recognized company with proven technology and business impact,” said Myungsu Chae, CEO of Nota AI. “Through this IPO, we aim to set a new global standard in AI optimization and accelerate the real-world adoption of AI across industries.”

Nota AI began its global expansion by establishing overseas offices in Germany and the United States. Since then, the company has rapidly scaled operations in regions including the Middle East, Japan, and Southeast Asia. With its technology-driven business model reaching maturity, Nota AI has grown its revenue nearly tenfold over the past five years. The company projects year-over-year growth exceeding 72% in 2025. IPO proceeds will be used to advance R&D and accelerate global business expansion.

SYDNEY, July 30, 2025 /PRNewswire/ — FranklinWH Australia Pty Ltd. (FranklinWH Australia), a leading global provider of home energy management and storage systems, is officially approved by Brighte to offer battery storage finance. This partnership will give numerous Australian homeowners easy and flexible access to reliable energy solutions.

There are two key financing paths through Brighte:

• A 0% Interest Payment Plan, with no interest charged over the loan term, perfect for budget-conscious homeowners.
• A Green Loan with competitive fixed interest rates, offering longer repayment terms and broader eligibility.

Both financing options are available for the purchase and installation of FranklinWH aPower batteries through Brighte-accredited installers. Homeowners can borrow up to $55,000, repay over terms of up to 10 years.

“This approval is a big win for both installers and homeowners,” said Steve Ruskin, GM of FranklinWH Australia/NZ. “It removes the upfront cost barrier by giving homeowners real financial flexibility.”

FranklinWH’s flagship home battery, the aPower X, offers a 13.6 kWh capacity with a 12-year warranty and can scale with multiple units to meet whole-home energy demands. The Brighte approval means homeowners don’t have to delay a home battery addition to their solar systems due to high upfront costs.

The partnership also unlocks advantages for FranklinWH’s installer network. Installers can now offer point-of-sale financing backed by Brighte’s financing platform, which helps accelerate deal closure, reduce drop-off rates, and improve customer satisfaction.

Both companies see this move as timely, given rising electricity prices, increased demand for backup power, and more government incentives for electric alternatives. FranklinWH and Brighte are confident the collaboration will help more Australians transition to more intelligent and reliable home energy.

About FranklinWH

FranklinWH is a market-oriented, research-driven company focused on next-generation residential energy management and storage solutions. Headquartered in the San Francisco Bay Area, FranklinWH’s team has decades of experience in energy systems, from design, through manufacturing, sales, installation, and service. 

About Brighte

Brighte, Australia’s leading affordability and accessibility platform for consumer energy resources (CER) helps homeowners upgrade to cleaner, smarter technology. Since 2015, Brighte has supported over 260,000 Australian households and funded more than A$2 billion in sustainable home improvements, including solar, batteries, and electrification systems.

Media Contacts:

FranklinWH: media@franklinwh.com

All applications are subject to Brighte’s credit approval criteria. Fees, Terms and Conditions apply. Australian Credit Licence Number 508217. Visit brighte.com.au for more information.

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).   

Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/x4gytx8w/

Participants can register for the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.) 
Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

This announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Genevieve Ryan.  

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2025 Telix Pharmaceuticals Limited. All rights reserved.

SUZHOU, China, July 30, 2025 /PRNewswire/ — The 7^th AI Product & Application Expo (“2025 AI Expo”), organized by the New Generation AI Industry Technology Innovation Strategic Alliance (AITISA), opened today in Suzhou. This year’s event focused on high-impact themes including embodied intelligence, digital transformation, and industrial AI. A full slate of exhibitions, forums, and matchmaking sessions was held to foster industry collaboration, accelerate technical breakthroughs, and enable cross-sector innovation—shaping conversations around the trajectory of AI and the evolving contours of the industry.

At the opening ceremony, three industry-defining reports were released: the Annual Report on New Generation AI Development (2024–2025), the China Urban AI Development Index Report (2024–2025), and the AI Industry Investment Trends and Development Report. These publications provide key benchmarks for tracking the progress of China’s AI ecosystem. The Expo also hosted a recognition ceremony for the 2025 AI Technology Leadership Talent Settlement Projects and presented awards for the 3rd AI Product & Application Innovation and Entrepreneurship Competition and the 2nd Zu Chongzhi Award for Frontier Innovation in Artificial Intelligence.

More than 20 high-profile product launches were unveiled at the new release showcase. The Expo also introduced a new “Black Tech” experience zone, where over 20 companies presented more than 200 cutting-edge technologies in an immersive demonstration space. The zone included on-site purchasing options, linking forward-looking innovation with real-world consumer engagement. To strengthen regional integration, the event expanded collaboration with Shanghai’s World Artificial Intelligence Conference (WAIC), promoting talent exchange, scenario-based deployment, and shared resource strategies across the Yangtze River Delta—reinforcing Suzhou’s role as a national model for AI+ application deployment.

Suzhou Industrial Park, the city’s engine of AI innovation, has played a leading role in advancing AI and digital industries since 2017. From the ground up, it has built an ecosystem for AI R&D, pilot applications, and industrial clustering. In recent years, the park has stepped up its “AI+” strategy, targeting next-wave technologies such as foundation models and embodied AI. It now hosts multiple national research centers and innovation platforms, and has attracted leading AI companies from China and abroad. As AI becomes more deeply embedded in the real economy, the park is driving the emergence of an AI-powered industrial cluster valued at over 100 billion yuan.

• CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System
• The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, to possibly enable earlier creation and use of AV fistula
• Results to be presented at American Society of Nephrology (ASN) Annual Meeting in November

SYDNEY and SAN ANTONIO, July 30, 2025 /PRNewswire/ — Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading provider of in-center and home dialysis in the United States, today announced the successful completion of enrollment in the CANSCAN clinical trial (NCT06691672). The first-of-its-kind, multi-center feasibility study enrolled 120 patients with chronic kidney disease to evaluate the use of semi-autonomous ultrasound scanning utilizing the VxWave Ultrasound Imaging System for arteriovenous (AV) fistula mapping in dialysis clinics.

The Vexev and U.S. Renal Care teams successfully completed enrollment in the CANSCAN trial. The study is evaluating the use of semi-autonomous ultrasound scanning with the VxWave Ultrasound Imaging System for AV fistula mapping in dialysis clinics.

“The VxWave ultrasound system may remove one of the biggest hurdles in the creation of vascular access. Patients could have vascular mapping conducted in their dialysis facility, enabling a more efficient way to obtain a permanent vascular access point,” commented Varshi Broumand, MD, MHA, FACP, FASN, Interventional Nephrologist at South Texas Renal Care Group and CANSCAN Study Principal Investigator. “Performing the ultrasound scans during the clinic visit would make AV fistula mapping more convenient and timely and potentially avoid sending patients to additional imaging appointments.”

An AV fistula is a connection made between an artery and a vein, typically in the arm, to create an access point for patients requiring dialysis. This allows blood to flow quickly and easily during treatment, which helps the body remove toxins more effectively. The VxWave Ultrasound Imaging System is a robotic tomographic ultrasound system specifically designed for upper limb vascular imaging – integrating advanced robotics, machine learning and ultrasound signal processing to create a 3D vascular model and detailed report that potentially provides insights into vascular access points – all at the point of care.

“Validating this concept is the first step toward a future where intelligent machines can perform high-precision medical imaging without a human hand on the probe. The potential for a robotic system guided by AI, delivering real clinical value – it’s not science fiction anymore,” said Shannon Thomas, MD, Chief Medical Officer, Vexev. “The real excitement begins when this can change lives, not just lab results. This is a huge step forward in our mission to improve the lives of millions of people worldwide living with end-stage kidney disease.”

“U.S. Renal Care is committed to delivering innovative treatments that address the most critical needs for people living with kidney disease,” said Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs, U.S. Renal Care. “The CANSCAN trial of the VxWave Ultrasound Imaging System opens the possibility of integrating semi-autonomous ultrasound imaging into our workflow and improving patient outcomes, by allowing patients to receive life-saving permanent vascular access placed in the optimal location, as quickly as possible.”

About Vexev
Vexev is an Australian med‑tech startup founded in 2018 by Drs. John Carroll and Eamonn Colley – University of New South Wales (UNSW) PhD graduates in vascular fluid dynamics and computational imaging. Vexev is on a mission to improve lives by developing the next generation of vascular imaging solutions. Visit Vexev.com to learn more.

About U.S. Renal Care
U.S. Renal Care, the fastest-growing dialysis provider in the nation, partners with nephrologists across 32 states in the U.S. to care for more than 36,000 people living with kidney disease. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence – delivering the best experience and outcomes for our patients. Visit USRenalCare.com to learn more.

Photo – https://laotiantimes.com/wp-content/uploads/2025/07/vexev_usrenal_canscan.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/07/vexev_logo.jpg